A biodevice for implanting insulin-producing cells in a diabetic patient without

Information

  • Research Project
  • 8338868
  • ApplicationId
    8338868
  • Core Project Number
    R43DK093145
  • Full Project Number
    5R43DK093145-02
  • Serial Number
    093145
  • FOA Number
    RFA-DK-10-008
  • Sub Project Id
  • Project Start Date
    9/27/2011 - 13 years ago
  • Project End Date
    8/31/2014 - 10 years ago
  • Program Officer Name
    ARREAZA-RUBIN, GUILLERMO
  • Budget Start Date
    9/1/2012 - 12 years ago
  • Budget End Date
    8/31/2014 - 10 years ago
  • Fiscal Year
    2012
  • Support Year
    02
  • Suffix
  • Award Notice Date
    9/1/2012 - 12 years ago
Organizations

A biodevice for implanting insulin-producing cells in a diabetic patient without

DESCRIPTION (provided by applicant): A closed loop, glucose sensing, and insulin responsive system could dramatically improve treatment options for insulin dependent diabetics. Current artificial systems, however, lack the ability to provide this precise control. Clinical islet transplantation, the intrahepatic loading of allogeneic islets, shows the potential to provide this intimate control, by transplanting the very cells with this inherent glucose sensing/insulin secreting capacity. Limiting islet transplantation, however, is the significant loss and dysfunction of islets following implantation, due to the poor engraftment environment and significant immunological attack. We have sought to address these roadblocks by developing two platform technologies for optimizing islet environment and blocking immune attack: 1) three dimensional scaffolds; and 2) micron thick conformal biomaterial coatings. Our long term goal is to converge these two platforms to reduce the islet load required for efficacy, minimize islet loss following transplant, and to dramatically reduce the need for systemic immunosuppression. In this proposal, we seek to optimize these promising platforms at the scale necessary for translation to the clinic. We seek to develop technologies to improve the efficiency and consistency of our macroporous scaffolds, as well as our conformal coating method. To achieve these aims, we seek to fabricate equipment and optimize protocols, as well as evaluate the efficacy of these platforms in pre-clinical models of diabetes. Our preliminary data strongly support the feasibility of this proposal, as well as our strategic collaborations with the Diabetes Research Institute at the University of Miami. Accomplishment of our aims will dramatically enhance the efficacy of islet transplantation, thereby providing a significant enhancement in treatment options for insulin dependent diabetics.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    447623
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:447623\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZDK1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CONVERGE BIOTECH, INC.
  • Organization Department
  • Organization DUNS
    009397710
  • Organization City
    MIAMI
  • Organization State
    FL
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    33136
  • Organization District
    UNITED STATES